Spot-Mas 女士10種早期癌症篩查 (HCDNA01)

SPOT‑MAS 是甚麼？
SPOT‑MAS 是一種利用血液樣本進行的「多癌種早期篩查」檢測（MCED），屬於非入侵性檢查，只需抽一管血。

利用「循環腫瘤 DNA(ctDNA)」技術，配合次世代定序（NGS）及人工智能分析，從血液中找出可疑的腫瘤訊號，並嘗試預測可能的腫瘤來源器官。

✅準確性高：結合基因組學、表觀基因組學和碎片組學，比單獨檢測突變更全面、更精準。高特異性99.8%，假陽性機會率極低。
✅針對亞洲人群：亞洲首個經9,024人前瞻性驗證的測試(1) (2)。
✅簡單便捷：只需抽血10ml，即可進行多種癌症檢測。
✅比影像檢查早發現癌症：比X光或CT更早發現癌症訊號(3)。

為何癌症篩查這麼重要？
本地癌症個案持續上升，很多病人發現時已屬中晚期，治療選擇及存活率較差。

早期發現癌症，接受適當治療時，5 年存活率可比晚期提升數倍。這一點在乳癌、大腸癌、肺癌等癌種的數據中都有體現。香港每天97宗新癌症病例(4)，早篩查可避免晚期診斷（如肺癌72%晚期(5)、大腸癌50%晚期(6)）

SPOT‑MAS女士10種早期癌症篩查可以篩查甚麼癌症？

• 肺癌

• 乳癌

• 大腸癌

• 胃癌

• 肝膽管癌

• 子宮內膜癌

• 食道癌

• 卵巢癌

• 胰臟癌

• 頭頸癌

参考資料 :

1. Nguyen, L.H.D, et al. Prospective validation study: a non-invasive circulating tumor DNA-based assay for simultaneous early detection of multiple cancers in asymptomatic adults. BMC Med (2023).
2. Carbonell, Chantelle, et al. Cancer Control (2024). 9. Data on file. 10. GBD 2019 Asia and All Cancers Collaborators. Temporal patterns of cancer burden in Asia, 1980-2019: a systematic examination for the Global Burden of Disease 2019 study. Lancet Rep Health Southeast Asia. 2024;2:1100333.
3. Nguyen LHD, et al. Prospective validation study: a non-invasive circulating tumor DNA-based assay for simultaneous early detection of multiple cancers in asymptomatic adults. BMC Med. 2025;23(1):90.

4. Hospital Authority, Overview of Hong Kong Cancer Statistics of 2022. Available from: https://www3.ha.org.hk/cancer/gd/pd/overview/Overview%20of%20HKG%20Cancer%20Stat%202022.pdf. [Accessed 28 May 2025].

5. Hong Kong Cancer Registry, Hospital Authority. Lung Cancer in 2020. Available from: https://www3.ha.org.hk/cancer/gd/pdf/factsheet/2020/lung_2020.pdf [Accessed 30 May 2025].

6. Centre for Health Protection. Non-Communicable Diseases Watch: Awareness and Prevention of Colorectal Cancer. January 2022. Available from: https://www.chp.gov.hk/files/pdf/ncd_watch_january_2022.pdf?f=text=Half%20(50.0%)%20of%20the%20new%20cases%20were,15.4%20of%20all%20cancer%20death%20in%202020. [Accessed 30 May 2025].